Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05291871 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunogenicity of Fractional Dose of the HPV Vaccines

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv6
  2. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2026v5
  3. Primary completion date: Dec 31, 2023 to Dec 31, 2024 Completion date: Dec 2024 to Dec 31, 2024v4 Show 1 more changeShow less
    • Completion date: Dec 2024 to Dec 31, 2024
  4. Primary completion date: Dec 2023 to Dec 31, 2023v3
  5. Trial status: Not Yet Recruiting to Active, Not Recruiting Enrollment target: estimated 100 to confirmed 92 · Study sites: 0 to 1 · Start date changed from estimate of Mar 2022 to Jun 15, 2022v2 Show 3 more changesShow less
    • Enrollment target: estimated 100 to confirmed 92
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2022 to Jun 15, 2022
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase IV trial compares intramuscular and intradermal fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, and 12 months
Trial Details
NCT Number NCT05291871
Lead Sponsor University of Washington
Conditions HPV Infection, HPV Vaccine
Enrollment 92 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov